PTCE Pharmacy Connect | Pharmacy Times

Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohi

Educational Objectives Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction Faculty: Robin Laird Patient Advocate Los Angeles, California Mary Barna Bridgeman, PharmD, BCPS,

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Title: Challenges in Treatment of Desmoid Tumors and Managed Car

To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to

Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Spe

Educational Objectives Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD Faculty: Amanda Hickman, PharmD, MPH, MSCS Central Support Pharmac

Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma. Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan Moderator: Laura R. Bobolts, P

Educational Objectives Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP) Recall the efficacy and safety of emerging agents for the treatment of ITP Moderator: Anthony J. Perissinotti, PharmD, BCOP To claim CE credit for this activity, please visit the link below: https://www.pharmacytimes.org/cou

The educational objectives are: • Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development • Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters Faculty: Dennis Williams Moderator: Jamie

Educational Objectives Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments Faculty: Joseph A. Kalis, PharmD, BCOP Ambulatory Oncology Pharmacist UCHealth Hematology/Oncology Colorado Springs, Colorado